million after deducting offering expenses . the notes are senior unsecured obligations and bear interest at a rate of 2.5 % per year , payable semi-annually in arrears on march 15 and december 15 of each year , beginning march 15 , 2015. the notes will mature on september 15 , 2021 , unless earlier converted , redeemed or repurchased . product license agreements rociletinib in may 2010 , we entered into an exclusive worldwide license agreement with avila therapeutics , inc. ( now celgene avilomics research inc. , part of celgene corporation ( “ celgene ” ) ) to discover , develop and commercialize a covalent inhibitor of mutant forms of the egfr gene product . as a result of the collaboration contemplated by the agreement , rociletinib was identified as the lead inhibitor candidate , which we are developing under the terms of the license agreement . 46 under the agreement , we are required to use commercially reasonable efforts to develop and commercialize rociletinib , and we are responsible for all preclinical , clinical , regulatory and other activities necessary to develop and commercialize rociletinib . we made an up-front payment of $ 2.0 million upon execution of the license agreement , a $ 4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the u.s. food and drug administration ( “ fda ” ) of our investigational new drug ( “ ind ” ) application for rociletinib and a $ 5.0 million milestone payment in the first quarter of 2014 upon the initiation of the phase ii study for rociletinib . we recognized all payments as acquired in-process research and development expense . when and if commercial sales of rociletinib commence , we will pay celgene tiered royalties at percentage rates ranging from mid-single digits to low teens based on annual net sales achieved . we are required to pay up to an additional aggregate of $ 110.0 million in regulatory milestone payments if certain clinical study objectives and regulatory filings , acceptances and approvals are achieved . in addition , we are required to pay up to an aggregate of $ 120.0 million in sales milestone payments if certain annual sales targets are achieved , the majority of which relate to annual sales targets of $ 500.0 million and above . in january 2013 , the company entered into an exclusive license agreement with gatekeeper pharmaceuticals , inc. ( “ gatekeeper ” ) to acquire exclusive rights under patent applications associated with mutant egfr inhibitors and methods of treatment . pursuant to the terms of the license agreement , the company made an up-front payment of $ 250 thousand upon execution of the agreement , which was recognized as acquired in-process research and development expense . if rociletinib is approved for commercial sale , the company will pay royalties to gatekeeper on future net sales . rucaparib in june 2011 , we entered into a license agreement with pfizer inc. to obtain the exclusive global rights to develop and commercialize rucaparib . the exclusive rights are exclusive even as to pfizer and include the right to grant sublicenses . under the terms of the license agreement , we made a $ 7.0 million up-front payment to pfizer . in april 2014 , the company initiated a pivotal registration study for rucaparib , which resulted in a $ 0.4 million milestone payment to pfizer as required by the license agreement . this payment was recognized as acquired in-process research and development expense . we are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib , and we are responsible for all remaining development and commercialization costs for rucaparib . when and if commercial sales of rucaparib begin , we will pay pfizer tiered royalties at a mid-teen percentage rate on our net sales , with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib . we are required to make regulatory milestone payments to pfizer of up to an additional $ 88.5 million if specified clinical study objectives and regulatory filings , acceptances and approvals are achieved . in addition , we are obligated to make sales milestone payments to pfizer if specified annual sales targets for rucaparib are met , the majority of which relate to annual sales targets of $ 500.0 million and above , which , in the aggregate , could amount to total milestone payments of $ 170.0 million . in april 2012 , the company entered into a license agreement with astrazeneca uk limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with parp inhibitors in certain indications . the license enables the development and commercialization of rucaparib for the uses claimed by these patents . pursuant to the terms of the license agreement , the company made an up-front payment of $ 250 thousand upon execution of the agreement , which was recognized as acquired in-process research and development expense . the company may be required to pay up to an aggregate of $ 0.7 million in milestone payments if certain regulatory filings , acceptances and approvals are achieved . if approved , astrazeneca will also receive royalties on any net sales of rucaparib . lucitanib on november 19 , 2013 , the company acquired all of the issued and outstanding capital stock of eos and gained rights to develop and commercialize lucitanib , an oral , selective tyrosine kinase inhibitor . as further described below , eos licensed the worldwide rights , excluding china , to develop and commercialize lucitanib from advenchen laboratories llc ( “ advenchen ” ) . story_separator_special_tag the assumptions related to determining the value of contingent consideration include significant judgment and changes to the assumptions may have a material impact on the amount of accretion of contingent purchase consideration expense recorded in any given period . the acquisition of eos in november 2013 resulted in the recognition of a contingent consideration liability , based on assumptions related to potential future payout amounts , estimated discount rate , probability of success for each milestone achievement and the estimated timing of the milestone payments to the former eos shareholders . intangible assets intangible acquired in-process research and development ( “ ipr & d ” ) assets were established as part of the purchase accounting of eos and are not amortized . amortization of these assets will commence when the useful lives of the intangible assets have been determined . ipr & d intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value would be recognized as an expense on the consolidated statements of operations . revenue recognition revenue is recognized from milestone payments when the following criteria have been met : ( 1 ) persuasive evidence of an arrangement exists ; ( 2 ) delivery has occurred or services have been rendered ; ( 3 ) the price is fixed or determinable ; and collectability is reasonably assured . we exercise judgment in determining that collectability is reasonable assured or that services have been delivered in accordance with the arrangement . we assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment . we assess collectability based primarily on the customer 's payment history and creditworthiness of the customer . payments that are contingent upon the achievement of a milestone will be recognized in the period in which the milestone is achieved . results of operations comparison of years ended december 31 , 2014 , 2013 and 2012 : license and milestone revenue . license and milestone revenue for the year ended december 31 , 2014 was due to the recognition of $ 13.6 million of milestone revenue from servier upon the end of opposition and appeal of the lucitanib patent by the european patent office in the first quarter of 2014. we did not recognize any revenue in 2013 and 2012. research and development expenses . research and development expenses for the years ended december 31 , 2014 , 2013 and 2012 were as follows : replace_table_token_6_th the increase in research and development expenses for the year ended december 31 , 2014 compared to 2013 was primarily due to expanded development activities for the rociletinib and rucaparib programs . costs associated with clinical and nonclinical development activities for rociletinib were $ 29.4 million higher than 2013 driven by higher enrollment in the ongoing phase i/ii study in nsclc , as well as the initiation of the tiger-1 , tiger-2 and japanese phase i studies in 2014. clinical trial costs for rucaparib were $ 11.8 million higher than the prior year primarily due to the initiation of the ariel2 and ariel3 studies in ovarian cancer . our development costs for rucaparib were also $ 3.4 million higher than 2013 due to the expansion of our collaboration with foundation medicine , inc. to incorporate a coordinated regulatory strategy for the development of a novel companion diagnostic test . clinical supply and related manufacturing development costs for both programs were $ 13.8 million higher than 2013 , as we increased production to support expanded clinical studies . in addition , salaries , share-based compensation expense and other personnel related costs were $ 13.2 million higher in 2014 driven by higher headcount to support our expanded development activities . these increases were partially offset by $ 4.4 million lower costs due to the termination of the ckit program in late 2013 . 52 research and development activities for rucaparib increased by $ 15.7 million in 2013 over 2012 primarily due to the initiation of the ariel2 and ariel3 clinical trials ( increase of $ 7.0 million ) and increased manufacturing of clinical drug supply to support all of the rucaparib clinical trials ( increase of $ 7.7 million ) . research and development activities for rociletinib increased by $ 9.3 million in 2013 over 2012. costs for the ongoing phase i/ii clinical trial for rociletinib increased by $ 1.9 million due to a larger number of patients enrolled in this study in 2013. in addition , we completed a clinical study related to a new formulation of rociletinib in 2013 , which increased clinical trial costs by $ 1.3 million . finally , the development of an improved formulation of rociletinib and increased manufacturing of drug supply to support the rociletinib clinical trials resulted in an increase of $ 6.1 million in research and development expenses . in 2013 , we performed a full year of drug discovery activities for ckit resulting in an increase of $ 2.3 million over 2012 for which costs commenced in the third quarter of 2012. salaries , share-based compensation expense and other personnel related costs for employees working on our research and development programs increased by $ 3.6 million during 2013 , as we increased headcount to support our expanded development activities . these increases in research and development expenses were partially offset by a $ 23.2 million decline in co-101 related expenses due to the termination of this program in late 2012. general and administrative expenses . general and administrative expenses for the years ended december 31 , 2014 , 2013 and 2012 were as follows : replace_table_token_7_th the increase in general and administrative expenses for the year ended december 31 , 2014 over 2013 was primarily attributable to $ 4.8 million higher share-based compensation expense . the increase in general and administrative expenses for the year ended december 31 , 2013 over 2012 was

liquidity and capital resources we have funded our operations through the private placement of preferred stock and convertible debt securities and the public offering of our common stock . as of december 31 , 2014 , we have received $ 278.3 million in net proceeds from the issuance of convertible senior notes , $ 75.5 million in net proceeds from the issuance of convertible preferred stock , $ 27.9 million through the issuance of convertible promissory notes , $ 458.4 million in net proceeds from the issuance of common stock and $ 4.4 million in proceeds from employee stock option exercises and stock purchases under our employee stock purchase plan . as of december 31 , 2014 , we had cash and cash equivalents totaling $ 482.7 million . the following table sets forth the primary sources and uses of cash for each of the periods set forth below : replace_table_token_10_th operating activities net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital . net cash used in operating activities increased $ 45.3 million for the year ended december 31 , 2014 compared to 2013 driven by higher rociletinib and rucaparib research and development costs associated with the expansion of clinical trials , drug formulation and manufacturing costs and higher salaries , benefits and personnel-related costs resulting from higher headcount to support the expanded development activities of our product candidates , partially offset by the milestone revenue payment received from servier .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have funded our operations through the private placement of preferred stock and convertible debt securities and the public offering of our common stock . as of december 31 , 2014 , we have received $ 278.3 million in net proceeds from the issuance of convertible senior notes , $ 75.5 million in net proceeds from the issuance of convertible preferred stock , $ 27.9 million through the issuance of convertible promissory notes , $ 458.4 million in net proceeds from the issuance of common stock and $ 4.4 million in proceeds from employee stock option exercises and stock purchases under our employee stock purchase plan . as of december 31 , 2014 , we had cash and cash equivalents totaling $ 482.7 million . the following table sets forth the primary sources and uses of cash for each of the periods set forth below : replace_table_token_10_th operating activities net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital . net cash used in operating activities increased $ 45.3 million for the year ended december 31 , 2014 compared to 2013 driven by higher rociletinib and rucaparib research and development costs associated with the expansion of clinical trials , drug formulation and manufacturing costs and higher salaries , benefits and personnel-related costs resulting from higher headcount to support the expanded development activities of our product candidates , partially offset by the milestone revenue payment received from servier .
```    
 Suspicious Activity Report : million after deducting offering expenses . the notes are senior unsecured obligations and bear interest at a rate of 2.5 % per year , payable semi-annually in arrears on march 15 and december 15 of each year , beginning march 15 , 2015. the notes will mature on september 15 , 2021 , unless earlier converted , redeemed or repurchased . product license agreements rociletinib in may 2010 , we entered into an exclusive worldwide license agreement with avila therapeutics , inc. ( now celgene avilomics research inc. , part of celgene corporation ( “ celgene ” ) ) to discover , develop and commercialize a covalent inhibitor of mutant forms of the egfr gene product . as a result of the collaboration contemplated by the agreement , rociletinib was identified as the lead inhibitor candidate , which we are developing under the terms of the license agreement . 46 under the agreement , we are required to use commercially reasonable efforts to develop and commercialize rociletinib , and we are responsible for all preclinical , clinical , regulatory and other activities necessary to develop and commercialize rociletinib . we made an up-front payment of $ 2.0 million upon execution of the license agreement , a $ 4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the u.s. food and drug administration ( “ fda ” ) of our investigational new drug ( “ ind ” ) application for rociletinib and a $ 5.0 million milestone payment in the first quarter of 2014 upon the initiation of the phase ii study for rociletinib . we recognized all payments as acquired in-process research and development expense . when and if commercial sales of rociletinib commence , we will pay celgene tiered royalties at percentage rates ranging from mid-single digits to low teens based on annual net sales achieved . we are required to pay up to an additional aggregate of $ 110.0 million in regulatory milestone payments if certain clinical study objectives and regulatory filings , acceptances and approvals are achieved . in addition , we are required to pay up to an aggregate of $ 120.0 million in sales milestone payments if certain annual sales targets are achieved , the majority of which relate to annual sales targets of $ 500.0 million and above . in january 2013 , the company entered into an exclusive license agreement with gatekeeper pharmaceuticals , inc. ( “ gatekeeper ” ) to acquire exclusive rights under patent applications associated with mutant egfr inhibitors and methods of treatment . pursuant to the terms of the license agreement , the company made an up-front payment of $ 250 thousand upon execution of the agreement , which was recognized as acquired in-process research and development expense . if rociletinib is approved for commercial sale , the company will pay royalties to gatekeeper on future net sales . rucaparib in june 2011 , we entered into a license agreement with pfizer inc. to obtain the exclusive global rights to develop and commercialize rucaparib . the exclusive rights are exclusive even as to pfizer and include the right to grant sublicenses . under the terms of the license agreement , we made a $ 7.0 million up-front payment to pfizer . in april 2014 , the company initiated a pivotal registration study for rucaparib , which resulted in a $ 0.4 million milestone payment to pfizer as required by the license agreement . this payment was recognized as acquired in-process research and development expense . we are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib , and we are responsible for all remaining development and commercialization costs for rucaparib . when and if commercial sales of rucaparib begin , we will pay pfizer tiered royalties at a mid-teen percentage rate on our net sales , with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib . we are required to make regulatory milestone payments to pfizer of up to an additional $ 88.5 million if specified clinical study objectives and regulatory filings , acceptances and approvals are achieved . in addition , we are obligated to make sales milestone payments to pfizer if specified annual sales targets for rucaparib are met , the majority of which relate to annual sales targets of $ 500.0 million and above , which , in the aggregate , could amount to total milestone payments of $ 170.0 million . in april 2012 , the company entered into a license agreement with astrazeneca uk limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with parp inhibitors in certain indications . the license enables the development and commercialization of rucaparib for the uses claimed by these patents . pursuant to the terms of the license agreement , the company made an up-front payment of $ 250 thousand upon execution of the agreement , which was recognized as acquired in-process research and development expense . the company may be required to pay up to an aggregate of $ 0.7 million in milestone payments if certain regulatory filings , acceptances and approvals are achieved . if approved , astrazeneca will also receive royalties on any net sales of rucaparib . lucitanib on november 19 , 2013 , the company acquired all of the issued and outstanding capital stock of eos and gained rights to develop and commercialize lucitanib , an oral , selective tyrosine kinase inhibitor . as further described below , eos licensed the worldwide rights , excluding china , to develop and commercialize lucitanib from advenchen laboratories llc ( “ advenchen ” ) . story_separator_special_tag the assumptions related to determining the value of contingent consideration include significant judgment and changes to the assumptions may have a material impact on the amount of accretion of contingent purchase consideration expense recorded in any given period . the acquisition of eos in november 2013 resulted in the recognition of a contingent consideration liability , based on assumptions related to potential future payout amounts , estimated discount rate , probability of success for each milestone achievement and the estimated timing of the milestone payments to the former eos shareholders . intangible assets intangible acquired in-process research and development ( “ ipr & d ” ) assets were established as part of the purchase accounting of eos and are not amortized . amortization of these assets will commence when the useful lives of the intangible assets have been determined . ipr & d intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value would be recognized as an expense on the consolidated statements of operations . revenue recognition revenue is recognized from milestone payments when the following criteria have been met : ( 1 ) persuasive evidence of an arrangement exists ; ( 2 ) delivery has occurred or services have been rendered ; ( 3 ) the price is fixed or determinable ; and collectability is reasonably assured . we exercise judgment in determining that collectability is reasonable assured or that services have been delivered in accordance with the arrangement . we assess whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment . we assess collectability based primarily on the customer 's payment history and creditworthiness of the customer . payments that are contingent upon the achievement of a milestone will be recognized in the period in which the milestone is achieved . results of operations comparison of years ended december 31 , 2014 , 2013 and 2012 : license and milestone revenue . license and milestone revenue for the year ended december 31 , 2014 was due to the recognition of $ 13.6 million of milestone revenue from servier upon the end of opposition and appeal of the lucitanib patent by the european patent office in the first quarter of 2014. we did not recognize any revenue in 2013 and 2012. research and development expenses . research and development expenses for the years ended december 31 , 2014 , 2013 and 2012 were as follows : replace_table_token_6_th the increase in research and development expenses for the year ended december 31 , 2014 compared to 2013 was primarily due to expanded development activities for the rociletinib and rucaparib programs . costs associated with clinical and nonclinical development activities for rociletinib were $ 29.4 million higher than 2013 driven by higher enrollment in the ongoing phase i/ii study in nsclc , as well as the initiation of the tiger-1 , tiger-2 and japanese phase i studies in 2014. clinical trial costs for rucaparib were $ 11.8 million higher than the prior year primarily due to the initiation of the ariel2 and ariel3 studies in ovarian cancer . our development costs for rucaparib were also $ 3.4 million higher than 2013 due to the expansion of our collaboration with foundation medicine , inc. to incorporate a coordinated regulatory strategy for the development of a novel companion diagnostic test . clinical supply and related manufacturing development costs for both programs were $ 13.8 million higher than 2013 , as we increased production to support expanded clinical studies . in addition , salaries , share-based compensation expense and other personnel related costs were $ 13.2 million higher in 2014 driven by higher headcount to support our expanded development activities . these increases were partially offset by $ 4.4 million lower costs due to the termination of the ckit program in late 2013 . 52 research and development activities for rucaparib increased by $ 15.7 million in 2013 over 2012 primarily due to the initiation of the ariel2 and ariel3 clinical trials ( increase of $ 7.0 million ) and increased manufacturing of clinical drug supply to support all of the rucaparib clinical trials ( increase of $ 7.7 million ) . research and development activities for rociletinib increased by $ 9.3 million in 2013 over 2012. costs for the ongoing phase i/ii clinical trial for rociletinib increased by $ 1.9 million due to a larger number of patients enrolled in this study in 2013. in addition , we completed a clinical study related to a new formulation of rociletinib in 2013 , which increased clinical trial costs by $ 1.3 million . finally , the development of an improved formulation of rociletinib and increased manufacturing of drug supply to support the rociletinib clinical trials resulted in an increase of $ 6.1 million in research and development expenses . in 2013 , we performed a full year of drug discovery activities for ckit resulting in an increase of $ 2.3 million over 2012 for which costs commenced in the third quarter of 2012. salaries , share-based compensation expense and other personnel related costs for employees working on our research and development programs increased by $ 3.6 million during 2013 , as we increased headcount to support our expanded development activities . these increases in research and development expenses were partially offset by a $ 23.2 million decline in co-101 related expenses due to the termination of this program in late 2012. general and administrative expenses . general and administrative expenses for the years ended december 31 , 2014 , 2013 and 2012 were as follows : replace_table_token_7_th the increase in general and administrative expenses for the year ended december 31 , 2014 over 2013 was primarily attributable to $ 4.8 million higher share-based compensation expense . the increase in general and administrative expenses for the year ended december 31 , 2013 over 2012 was

